Cellular senescence is a stress-responsive cell-cycle arrest program that terminates the further expansion of (pre-)malignant cells 1, 2 . Key signalling components of the senescence machinery, such as p16 INK4a , p21 CIP1 and p53, as well as trimethylation of lysine 9 at histone H3 (H3K9me3), also operate as critical regulators of stem-cell functions (which are collectively termed 'stemness') 3 . In cancer cells, a gain of stemness may have profound implications for tumour aggressiveness and clinical outcome. Here we investigated whether chemotherapy-induced senescence could change stemcell-related properties of malignant cells. Gene expression and functional analyses comparing senescent and non-senescent B-cell lymphomas from Eμ-Myc transgenic mice revealed substantial upregulation of an adult tissue stem-cell signature, activated Wnt signalling, and distinct stem-cell markers in senescence. Using genetically switchable models of senescence targeting H3K9me3 or p53 to mimic spontaneous escape from the arrested condition, we found that cells released from senescence re-entered the cell cycle with strongly enhanced and Wnt-dependent clonogenic growth potential compared to virtually identical populations that had been equally exposed to chemotherapy but had never been senescent. In vivo, these previously senescent cells presented with a much higher tumour initiation potential. Notably, the temporary enforcement of senescence in p53-regulatable models of acute lymphoblastic leukaemia and acute myeloid leukaemia was found to reprogram non-stem bulk leukaemia cells into self-renewing, leukaemia-initiating stem cells. Our data, which are further supported by consistent results in human cancer cell lines and primary samples of human haematological malignancies, reveal that senescence-associated stemness is an unexpected, cellautonomous feature that exerts its detrimental, highly aggressive growth potential upon escape from cell-cycle blockade, and is enriched in relapse tumours. These findings have profound implications for cancer therapy, and provide new mechanistic insights into the plasticity of cancer cells.
. In cancer cells, a gain of stemness may have profound implications for tumour aggressiveness and clinical outcome. Here we investigated whether chemotherapy-induced senescence could change stemcell-related properties of malignant cells. Gene expression and functional analyses comparing senescent and non-senescent B-cell lymphomas from Eμ-Myc transgenic mice revealed substantial upregulation of an adult tissue stem-cell signature, activated Wnt signalling, and distinct stem-cell markers in senescence. Using genetically switchable models of senescence targeting H3K9me3 or p53 to mimic spontaneous escape from the arrested condition, we found that cells released from senescence re-entered the cell cycle with strongly enhanced and Wnt-dependent clonogenic growth potential compared to virtually identical populations that had been equally exposed to chemotherapy but had never been senescent. In vivo, these previously senescent cells presented with a much higher tumour initiation potential. Notably, the temporary enforcement of senescence in p53-regulatable models of acute lymphoblastic leukaemia and acute myeloid leukaemia was found to reprogram non-stem bulk leukaemia cells into self-renewing, leukaemia-initiating stem cells. Our data, which are further supported by consistent results in human cancer cell lines and primary samples of human haematological malignancies, reveal that senescence-associated stemness is an unexpected, cellautonomous feature that exerts its detrimental, highly aggressive growth potential upon escape from cell-cycle blockade, and is enriched in relapse tumours. These findings have profound implications for cancer therapy, and provide new mechanistic insights into the plasticity of cancer cells.
Cellular senescence, which is implemented in response to severe cellular insults such as oncogenic activation or chemotherapeutic DNA damage, is a failsafe program that protects organismic integrity by excluding potentially harmful cells from further expansion 2, 4 , and also has a physiological function in tissue homeostasis during organ development 1 . Senescence has been shown to cancel the pro-tumorigenic potential of Ras-/Raf-driven (pre-)cancerous lesions [5] [6] [7] , and to contribute to the outcome of anticancer chemotherapy in vivo 8, 9 .
Notably, stem-cell functions, collectively referred to as 'stemness' 3 , and senescence seem to be co-regulated by overlapping signalling networks. Key senescence-relevant signalling molecules (for example, Bmi-1, p16 Ink4a , p21
Cip1 or p53) have critical roles in stem-cell maintenance by preventing premature exhaustion (reviewed in ref.
3). Senescence-enforcing p53 (also known as Trp53)-, Cdkn2a (also known as Ink4a or Arf)-or Suv39h1-encoded gene products raise an initial barrier to the efficient conversion of normal cells into induced pluripotent stem cells (see refs 10, 11 , and references therein), suggesting an underexplored interplay between senescence-and stemness-controlling signalling networks. Trimethylation of H3K9, as mediated by the H3K9 methyltransferase Suv39h1 (ref. 12), confers senescence by establishing a transcriptionally repressive heterochromatin mark in the vicinity of S-phase-relevant E2F target genes 6, 9, 13 , and reflects an epigenetic principle linked to induced pluripotent stem cell reprogramming 14 . Using a cancer-unrelated, inducible reprogramming mouse model in which many cells primarily senesced, previous studies have shown that factors secreted from these senescent cells facilitated the reprogramming of their neighbours 15, 16 . Whether the senescence condition promotes cancer stemness, especially in a cell-autonomous manner, is not known. Although a permanent senescent cell-cycle block is per se incompatible with self-renewal, we report here the senescence-evoked cell-intrinsic reprogramming of cancer cells into a stem-like state, and the acquisition of tumour-initiating potential after their forced release or spontaneous escape from a chemotherapy-induced senescent cell-cycle arrest.
As indicated by their strong senescence-associated β -galactosidase (SA-β -gal) activity and other previously demonstrated markers of senescence, primary Eμ -Myc transgenic Bcl2-overexpressing lymphomas (hereafter referred to as control;Bcl2 lymphomas) serve as a well-established model for therapy-induced senescence (TIS) 8, 9 . First, we analysed stem-cell-related transcripts in the gene expression profiles of 12 matched pairs of primary control;Bcl2 lymphomas that either entered TIS after in vitro exposure to the chemotherapeutic agent Adriamycin (ADR) or remained untreated. Using gene set enrichment analysis (GSEA), a previously established adult tissue stem-cell (ATSC) signature 17 was strongly skewed towards the TIS group, but was not found to be enriched in the equally ADR-treated but senescenceincapable group of Suv39h1-deficient Eμ -Myc;Bcl2 (that is, Suv39h1 − ;Bcl2) lymphomas 9 ( Fig. 1a and Extended Data Fig. 1a, b ). Almost the entire population turned double-positive for the stem-cell antigen Sca1 and the senescence marker H3K9me3 upon senescence induction (Fig. 1b, top) . Furthermore, TIS cells, unlike non-senescent cells, presented with increased aldehyde dehydrogenase (ALDH) and ATP-binding cassette (ABC) transporter activities (Fig. 1b , bottom, and Extended Data Fig. 1d ), both typical properties of stem cells. When assessing human malignancies of various origins, we found a notable upregulation of stem-cell-related transcripts selectively in TIS-capable cell lines as well as samples from patients with primary B-cell chronic leukaemia (B-CLL) ( Fig. 1c and Extended Data Fig. 1c, e, f) . Moreover, the acquisition of stemness-related properties can also be found in the process of oncogene-induced and replicative senescence in cells of various tissue types, including melanocytes, colon mucosa and breast epithelial cells (Fig. 1d and Extended Data Fig. 1g ). Hence, cancer cells of mouse and human origin acquire novel stem-cell features upon entering cellular senescence.
To test whether senescence-associated stemness (SAS) translates into different tumour behaviour upon release from the division block, we generated switchable model systems (using 4-hydroxytamoxifen (4-OHT)-inducible essential senescence mediators Suv39h1 or p53) that can enter full-featured senescence with increased levels of stemcell-related transcripts and proteins only when exposed to both 4-OHT and ADR ( Fig. 2a and Extended Data Fig. 2a-c) . After changing to ADR-and 4-OHT-free medium to switch Suv39h1 or p53 off again, single-cell analyses revealed that senescent cells resumed sustainable proliferation within a few days; that is, they became first doublepositive for the retained fluorescence-based senescence marker (a vital stain) and 5-ethynyl-2′ -deoxyuridine (EdU) incorporation, indicating restarted DNA synthesis (with the proliferation-repressive H3K9me3 mark gradually vanishing), before SA-β -gal activity was eventually lost and S-phase activity fully regained ( Fig. 2a and Extended Data Fig. 2d-g ). Therefore senescence is, in principle, a reversible condition, which becomes evident when essential senescence maintenance genes are no longer expressed. Importantly, serial replatings in colonyformation experiments of such previously senescent cells led to significantly more colonies compared to the aliquot of never senescent cells P a t ie n t 1 P a t ie n t 2 P a t ie n t 3 P a t ie n t 4
Figure 1 | Therapy-induced senescent cancer cells acquire phenotypic and functional stemness features. a, GSEA of an adult tissue stem cell profile 17 (ATSC; top) in matched pairs of ADR-exposed versus untreated control;Bcl2 lymphomas (n = 12; left) and Suv39h1 − ;Bcl2 lymphomas (n = 5; right). TIS lymphomas display more than 80% SA-β -gal-positive blue cells 9 (representative photomicrographs from four independent experiments). b, Co-expression of the stem cell marker Sca1 and the TIS marker H3K9me3 (top) in lymphoma cells as in a, and aldehyde dehydrogenase (ALDH) activity with and without the ALDH inhibitor diethylaminobenzaldehyde (bottom) by flow cytometry. Mean percentage of positive cells ± s.d.; n = 5 biologically independent samples each. c, Expression of the indicated stem-cell-related genes in various human cancer cell lines or primary B-CLL samples by quantitative PCR (qPCR), related to their ability to enter TIS (ADR-senescent, blue; non-senescent despite ADR exposure, white (see Extended Data Fig. 1c for details) − ;Bcl2;Suv39h1-ER T2 lymphoma cells after five days of ADR ± 4-OHT treatment (treatment), and subsequent passages in 4-OHT/ADR-free medium (post-treatment, p1-p2; each passage reflecting seven days in culture) presented as proliferation (left, mean BrdU/PImarked S-phase fraction ± s.d., n = 5 biologically independent samples; BrdU, 5-bromo-2′ -deoxyuridine; PI, propidium iodide), SA-β -gal staining (middle, mean positive cells ± s.d., n = 5 biologically independent samples), and colony formation (right, quantified in b). Flow microscopy images (bottom) of the fluorescent SA-β -gal mark together with the proliferation marker EdU (passage 1 shown, see Extended Data Fig. 2g for details) demonstrates the outgrowth of senescent (SA-β -gal + ) cells. Representative photomicrographs from four independent experiments. b, Colony counts of lymphoma cells (treated as in a) in extended serial passaging (p1-p14). Graphs show mean colony numbers ± s.d., n = 3 individual lymphomas. Two-tailed unpaired t-test with Welch's correction, comparing ADR-and 4-OHT+ ADR pretreated cells at p14. * P < 0.05. c, Tumour initiation after transplantation of different numbers of Suv39h1 − ;Bcl2;Suv39h1-ER T2 lymphoma cells pre-exposed to the indicated treatments in vitro. Bars reflect numbers of lymphoma-bearing mice out of 10 animals per group transplanted, within an observation period of up to 100 days. P < 0.001 for comparing never senescent and previously senescent groups (χ 2 ). letter reSeArCH of the same lymphoma treated with the same dose of chemotherapy, reflecting the now unleashed stemness properties acquired as a latent program during senescence (Fig. 2a, b) . The enhanced colony-founding potential of previously senescent cells was stable over an extended observation period of up to 100 days (reflecting 14 serial replatings; Fig. 2b ). Similar results were obtained with p53-ER TAM as another inducible senescence gatekeeper; with γ -irradiation as an alternative senescence trigger; with ADR-exposed human lymphoma cell lines; and with colon cancer cells representing a solid, epithelial cancer type (Extended Data Fig. 3a-f) . It is noteworthy that previously senescent cells typically retained the ability to re-enter TIS when re-exposed to 4-OHT and ADR, indicating that no selection for senescencecompromising mutations occurred in previously senescent cells (Extended Data Fig. 3g ). Previously, an instructive, non-cell-autonomous role has been attributed to the senescence-associated secretory phenotype (SASP; reviewed in ref.
2) in models of inducible reprogramming and tissue regeneration 15, 16 ; however, our observations, made in pure, homotypic tumour cell populations, even under drastic reduction of SASP factor expression, favour a largely cell-intrinsic mechanism of senescence-associated reprogramming (Extended Data Fig. 4 ). Although we cannot completely exclude alternative explanations, these and the subsequent data strongly favour senescence-associated stemness as the most compelling and consistent interpretation of the observations presented.
Enrichment assays between matched pairs of never senescent versus previously senescent lymphomas confirmed the higher growth competitiveness of previously senescent lymphomas both in vitro and in vivo (Extended Data Fig. 2h ). Importantly, in vivo tumour initiation experiments found previously senescent lymphomas produced malignancies at much lower transplanted cell numbers in immunecompetent recipient mice when compared to never senescent lymphomas (Fig. 2c) . Taken together, the SAS program exerts its detrimental effect on tumour initiation upon release from TIS, thereby unmasking an unexpected tumour-promoting capability of the senescence program.
To test which key stemness pathways drive SAS, we used GSEA in ADR-exposed control;Bcl2 versus Suv39h1 − ;Bcl2 lymphomas for numerous gene sets related to Notch, Hedgehog, and canonical and non-canonical Wnt signalling. Canonical Wnt and, to some extent, Notch signalling, appeared to be significantly enriched in TIS (Extended Data Fig. 5a, b) . Because Wnt signalling plays a central role in stem-cell renewal in many tissues including the haematopoietic compartment, induces Notch signalling, and is required for cancer stem cell development in haematological malignancies 18, 19 , we considered activation of the Wnt cascade as the putative driver behind the newly acquired stemness features in TIS lymphomas. Indeed, we detected enhanced, predominantly nuclear expression and transcriptional activation of β -catenin in control;Bcl2 but not in Suv39h1 − ;Bcl2 lymphomas, as well as in TIS-capable human cancer cell lines after ADR treatment (Fig. 3a , Extended Data Fig. 2b and Extended Data Fig. 5c, d) . Independent of Wnt ligand-receptor stimulation, we identified inhibition of the β -catenin degradation-promoting glycogen synthase kinase 3β (GSK3β ) via activated MEK-MAPK and PI3K-Akt signalling-which is typically upregulated in senescence 20 -as the cell-autonomous driver of the Wnt program (Extended Data Fig. 6 ). The implementation of the Wnt program was further promoted by epigenetically permissive remodelling at promoters of stem-cell-and Wnt signalling-related genes in previously senescent as compared to never senescent cells (Fig. 3b) . Accordingly, we found that the increased colony-forming potential of previously senescent lymphoma or colon cancer cells was dependent on Wnt signalling, as genetic or pharmacological disruption of the Wnt-β -catenin cascade-without preventing TIS or profoundly affecting cell viability-neutralized the higher clonogenicity of previously senescent cells ( Fig. 3c and Extended Data Fig. 7a-d) . In contrast to the never senescent cell population, a rarely dividing and strongly β -catenin-expressing subpopulation was detectable in the previously senescent cells only, and maintained at a stable steady state, explaining the lastingly enhanced colony-forming potential of previously senescent compared to never senescent cells (Extended Data Fig. 8 ). Consistently, the biology of the previously senescent state translated into shortened survival when previously senescent and never senescent cells were propagated in mice, whereas exposure to Wnt inhibitors in vivo or stable lymphoma cell transduction with a construct expressing short hairpin RNA (shRNA) against Ctnnb1 (which encodes β -catenin) improved the poor long-term outcome of mice harbouring previously senescent lymphomas ( Fig. 3d and Extended Data Fig. 7b , e, f).
Importantly, cell cycle re-entry out of TIS-as a prerequisite to exert stem-cell potential-is not limited to conditional, switchable systems, but may, as a rare event, spontaneously occur in control;Bcl2 lymphomas, as demonstrated by the emergence of EdU-co-positive cells out of a solely SA-β -gal-positive senescent cell population (Extended Data Fig. 9 ). Given their stem-cell potential, we postulated that β -cateninpositive previously senescent cells might be enriched in lymphomas that progressed after chemotherapy. Hence, when comparing primary control;Bcl2 lymphomas before therapy with the same individual lymphomas that had relapsed after exposure to senescence-inducing cyclophosphamide chemotherapy in vivo 8 , we found a much higher fraction of cells positive for nuclear β -catenin in relapse lymphomas that also presented with higher expression levels of Wnt target genes (Fig. 3e, f, left) . Moreover, longitudinally matched biopsy pairs from the same individual patients diagnosed with diffuse large B-cell lymphoma (DLBCL) before chemotherapy and at disease recurrence revealed significantly more nuclear β -catenin-positive tumour cells in the previously chemotherapy-exposed, re-emerging samples (Fig. 3f, right) , further supporting a link between activated Wnt signalling in relapsed tumours and senescence-related tumour cell reprogramming. Taken together, TIS-associated stemness reflects a Wnt-governed capability that is stably maintained in a reprogrammed, hierarchically organized subpopulation of post-senescent tumour cells and critically associated with tumour progression and treatment failure.
As presumably applying to various human tumours including aggressive lymphomas, Eμ -Myc transgenic mouse lymphomas do not originate from a distinct fraction of cancer stem cells, because almost all lymphoma cells possess tumour-initiating potential in this model 21 . Consequently, next we asked whether cellular senescence might account for the reprogramming of non-stem tumour cells into cancer stem cells 22 , in tumour types in which the tumour-initiating capacity is confined to a rare subpopulation. We isolated a non-self-renewing population of leukaemia cells from a mouse model of T-cell acute lymphoblastic leukaemia (T-ALL) driven by oncogenic Kras G12D and conditional inactivation of p53 via a doxycycline-controlled shRNA (shp53) 23 (Extended Data Fig. 10a ). ADR exposure induced senescence in the majority of non-stem leukaemia cells only if p53 expression was not cancelled (Fig. 4a, top) . This group exhibited a significant conversion to Kit
+

Sca1
+ cells, indicative of putative leukaemia stem cells (P = 0.02, compared to ADR-exposed but p53-deficient cells; Fig. 4a , middle), and higher expression of stem-cell-related transcripts (Fig. 4a , bottom). Upon release from TIS by knockdown of p53, these leukaemia cells resumed proliferation (thereby becoming previously senescent cells), and formed significantly more colonies as compared to their equally ADR-treated never senescent leukaemia counterparts that remained p53-inactive throughout the experiment (Extended Data  Fig. 10b ). As reported for TIS lymphomas, cells with nuclear β -catenin expression were almost exclusively detectable in the senescent leukaemia cell population, and Wnt inhibitors completely neutralized the increased colony formation potential of their previously senescent progeny (Extended Data Fig. 10c, d samples of never senescent cells-initiated leukaemias in recipient mice (P = 0.0275, comparing previously senescent and never senescent groups); as expected, all Lin − transplants gave rise to leukaemias (P < 0.001, comparing Lin − and never senescent groups; Fig. 4b, c) . Notably, and further adding to SAS in oncogene-induced senescent colon mucosa cells or melanocytes (compare with Fig. 1d ), TIS reprogramming is not restricted to cells of lymphoid origin, as demonstrated for an acute myeloid leukaemia (AML) mouse model 24 , cultureestablished human AML cells, and primary human leukaemic blast samples obtained at diagnosis from patients with AML (Extended Data Fig. 10e-l) . Thus, cellular senescence is not only associated with additional stem-cell features in tumour cells with pre-existing self-renewal capability, but also catalyses the cell-autonomous reprogramming of non-stem bulk tumour cells of lymphoid and non-lymphoid origin into de novo cancer stem cells.
We present here an unexpected cell-intrinsic link between the senescence program and the acquisition of self-renewing properties, which we postulate serves as a physiological rescue mechanism in development and tissue homeostasis. We and others have observed that senescence not only occurs in critically stressed cells, but also may spread to adjacent cells via SASP components in a paracrine fashion (ref. 25; J.R.D. and C.A.S., unpublished observations). We propose that nature equipped normal cells with a latent SAS capacity (compare with Extended Data Fig. 1g ) to counter the imminent loss of an entire tissue compartment due to pro-apoptotic and pro-senescent stresses: in rare cells spontaneously re-entering the cell cycle when threatening stresses no longer apply, SAS may become a tissue-replenishing principle. In a neoplastic context, cellular senescence-particularly in tumour cells with apoptotic defects-appears to be primarily a beneficial response by keeping tumour growth in check. However, post-senescent cells with 'hijacked' SAS exert their detrimental potential at relapse by driving a much more aggressive growth phenotype. Therefore, pharmacological strategies to specifically eliminate senescent cells before a fraction of them may implement their acquired stemness capacity become, as previously reported by us regarding cancer 9 and by others regarding ageing-related pathologies 26, 27 , a critical therapeutic need.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. . Genotyping of the offspring by allele-specific genomic PCR, monitoring of lymphoma onset and isolation of viable lymphoma cells were carried out as described 8, 34 . Kras
G12D
;shp53-GFP-induced T-cell acute lymphoblastic leukaemias (T-ALL) with tetracycline (that is, doxycycline)-dependent shp53 expression ('DOX-on') were generated and isolated following a previously published protocol with minor modifications 23, 35 . The Nras G12D /MLL-AF9-driven mouse model of acute myeloid leukaemia (AML), co-expressing a reverse tetracycline transactivator ('Tet-on competent'), was generated as previously described 24 . Sixto eight-week-old C57BL/6 ('wild type') female mice were used as recipients for in vivo lymphoma or leukaemia propagation. No randomization or blinding was used to allocate experimental groups.
The use of tumour biopsies (that is, bone marrow aspirates, lymph-node biopsies or peripheral blood samples obtained for the initial diagnosis or follow-up analyses of patients with B-cell leukaemia (B-CLL), diffuse large B-cell lymphoma (DLBCL) or acute myeloid leukaemia (AML)) as anonymous samples after informed patient consent was approved by the local ethics commission of the Charité -Universitätsmedizin Berlin (reference EA4/085/07 and EA4/061/11). Cell culture, plasmids and retroviral gene transfer. Isolated mouse lymphoma cells and primary human AML samples (tumour-cell-purified by Ficoll densitygradient centrifugation and red cell lysis) were short-term cultured in standard medium on irradiated NIH3T3 fibroblast feeders 36 . Primary human B-cell malignancies were cultivated in a 'CD40 system' 37 , that is, in the same medium further supplemented with 100 IU ml ;shp53-GFP T-ALL leukaemia samples, recipient mice were irradiated with 6 Gy, 24 h before transplantation. DOX was supplied with the drinking water (20 mg ml ; exchanged twice a week) and in food pellets (200 mg kg −1 of regular chow). Leukaemia manifestation was diagnosed by flow cytometry-based detection of GFP-positive cells in the peripheral blood at the time mice presented with general signs of pre-terminal sickness (greater than 20% weight loss or other symptoms of severe sickness). If no signs of sickness were noted, the experiments were ended by 70% tumour burden in peripheral blood. Lymphoma formation was diagnosed when palpable lymph-node enlargements had formed. A tumour size of 16 mm (corresponding to approximately 4 lymph nodes of 4 mm in diameter) was approved by Landesamt Berlin as an experiment end-point criterion and was not exceeded in any of the performed experiments. ICG-001 and salinomycin were applied intraperitoneally daily (both at a dose of 10 mg kg −1 body weight), starting from palpable lymphoma formation until a pre-terminal disease stage was reached. Time-to-death was defined as the latency between transplantation and a pre-terminal disease stage. Upon CO 2 euthanasia, single-cell suspensions were isolated from enlarged organs as described previously 8, 36 . Analysis of growth parameters, viability, stem-cell and senescence markers. Cellcycle analysis by 5-bromo-2′ -deoxyuridine/propidium iodide (BrdU/PI)-based flow cytometric measurement was performed as described previously 33 . Cytospin preparations of suspension cultures for subsequent SA-β -gal analyses or immunostainings were carried out as described previously 6, 44, 45 . Carboxyfluorescein succinimidyl ester (CFSE) labelling was performed on day 3 after starting ADR ± 4-OHT treatment, using the CellTrace Far Red Cell Proliferation Kit for flow cytometry (Molecular Probes, C34564) according to the manufacturer's recommendations. CFSE high cells were sorted on treatment day 5 on an S3e Cell Sorter (Bio-Rad). For β -catenin co-staining, CFSE-labelled cells were fixed in 4% paraformaldehyde, permeabilized by Saponin in 1% bovine serum albumin (LifeTechnologies, 10635), stained with Alexa Fluor 488 mouse anti-β -catenin antibody according to the manufacturer's recommendations (BD Pharmingen, 562505), and acquired on an ImageStreamX Mark II Imaging Flow Cytometer (Amnis, MerckMillipore). EdU labelling was performed on treatment day 5 using the Click-iT EdU Pacific Blue Flow Cytometry Assay Kit according to the manufacturer's recommendations (Molecular Probes, C10418). For the fluorescent SA-β -gal labelling, cells letter reSeArCH were incubated in 75 μ M chloroquine solution for 1 h followed by exposure to the C12FDG substrate (5-dodecanoylaminofluorescein-di-β -d-galactopyranoside; ImaGene Green C12FDG lacZ Gene Expression Kit, Molecular Probes, I2904) for 20 min at 37 °C in PBS (pH 5.5, with 1 mM MgCl 2 ) and analysed on ImageStreamX Mark II Imaging Flow Cytometer. Cell viability was evaluated by annexin V (BD Pharmingen, 556419) and propidium iodide (5 μ g ml −1 , Sigma-Aldrich) staining, analysed in a FACSCalibur flow cytometer (BD Biosciences). Viable cells were detected as annexin V/propidium iodide-double-negative. ABC transporter activity was analysed using the eFluxx-ID Gold multidrug resistance kit (Enzo Life Sciences), and ALDH activity using the ALDEFLUOR kit (StemCell Technologies) 46 , according to the manufacturer's instructions. Colony-forming unit assays were performed by plating 10 2 or 10 3 cells in 1 ml of methylcellulose medium (MethoCult M3134 for ), ICG-001 (10 μ M), salinomycin (1 μ M) 47, 48 , Wnt3a (10 ng ml The list of 5,401 probe sets differentially expressed between untreated and ADRtreated control;Bcl2 lymphomas was determined by analysis of variance (ANOVA, cut-off at q < 0.05). The list of filtered genes was ranked according to expression fold changes, and the genes belonging to the ATSC 17 or core embryonic stem-cell signature 49 were marked in orange and blue, respectively. Gene set enrichment analysis (GSEA) was performed with the GSEA v2.0 software (Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard, http://www.broad.mit.edu/gsea) 50 on transcriptome data produced in our laboratory (GSE31099 and GSE44355) or on publicly available transcriptome datasets downloaded from the Gene Expression Omnibus (GEO; https://www. ncbi.nlm.nih.gov/geo/): normal colon epithelium and colon adenomas from Apc Min/+ mice (GSE422, samples GSM6191-GSM6201), Braf-V600E-infected human melanocytes (GSE46801), human mammary epithelial cells in p16
INK4a
dependent stasis or telomere shortening-induced agonescence (GSE16058), normal human foreskin BJ fibroblasts in replicative senescence (GSE13330, samples GSM336385-GSM336628) and normal human mesenchymal stem cells in replicative senescence (GSE9593, samples GSM242185, GSM242668, GSM242669 and GSM242672-GSM242674). Probed gene sets were taken without further change from the indicated publications, downloaded from the Molecular Signature Database (MsigDB) of the Broad Institute (http://software.broadinstitute.org/gsea/ msigdb/collections.jsp) or from the Gene Ontology (GO) browser AmiGO ('GO Cell cycle process' (GO:0022402), GO 'Wnt signaling pathway' (GO0016055), GO 'Canonical Wnt receptor signaling' (GO:0060070), GO 'Noncanonical Wnt signaling' (GO0035567), GO 'Notch signaling pathway' (GO0007219), GO 'Smoothened signaling pathway' (GO0007224)), or generated from the gene list reflecting the Mouse Wnt Signalling Pathway PCR Array (SA Biosciences; genes from this list annotated to have a role in cell growth and proliferation were used as a separate gene set, http://www.sabiosciences.com/rt_pcr_product/HTML/PAMM-043A.html#function). Normalized enrichment scores (NES) with P values < 0.05 and false discovery rates (FDR) < 0.25 were considered statistically significant.
For quantitative reverse-transcriptase PCR analyses of stem-cell-related genes in lymphoma cells, RNA extracted with Trizol (Invitrogen) was transcribed into cDNA using SuperScript II reverse transcriptase (Invitrogen). A panel of established stem-cell-related markers consisting of mouse Abcg2, Cebpb, Kit, Cd34, Cd44, Prom1 (also known as Cd133), Slamf1 (also known as Cd150), Klf4, Ly6a (also known as Sca1) or human ABCG2, CD34, CD44, PROM1 (also known as CD133), SLAMF1 (also known as CD150), LGR5, a panel of Wnt signalling targets: Ccnd1, Fosl1, Fzd3, Id2, Met, as well as a panel of established mouse SASP factors: Igfbp6, Ccl2, Ccl20, Cxcl1, Ctgf, Il6, Kitl and Tnfa were analysed by qPCR using commercially available Taqman assays (Applied Biosystems). Transcript quantification was calculated as 2 (−ΔCt) based on Δ C t = Δ C t(treated) − Δ C t(untreated) , with GAPDH transcript levels as an internal control. Protein-based expression analyses. Immunophenotyping by flow cytometry was carried out as described previously 8, 45 , using the primary antibodies directed against human CD34 (BD Biosciences For immunoblotting analyses, whole-cell pellets were lysed in Laemmli sample buffer (60 mM Tris-HCl at pH 6.8, 10% glycerol, 2% SDS, 5% 2-mercaptoethanol) supplemented with protease and phosphatase inhibitors, resolved by electrophoresis on a 12% SDS polyacrylamide gel (SDS-PAGE), transferred onto an Immobilon-P membrane (Millipore) and probed using antibodies against total β -catenin (BD Biosciences, 610153, 1:200), active β -catenin (dephosphorylated at serine 37 (Ser37) and threonine 41 (Thr41); Millipore, 05-665, 1:1,000), H3K9me3 (Abcam, ab8898, 1:2,000), total Erk (Cell Signaling Technology (CST), 9102, 1:1,000), phospho-Erk1/2 (that is, Erk1/2 phosphorylated at Thr202 and Tyr204; CST, 4376, 1:1,000), total Akt (CST, 9272, 1:1,000), phospho-Akt (that is, Akt-PSer473; CST, 4060, 1:2,000), total GSK3β (CST, 12456, 1:1,000), phospho-GSK3β (that is, GSK3β -P-Ser9; CST, 5558, 1:1,000) and α -tubulin (Sigma, T5168, 1:500) as a loading control.
For immunofluorescence, cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100/PBS, blocked in 1% bovine serum albumin supplemented with the anti-mouse Cd32/Cd16 antibody (BD Biosciences, 53142, 1:50) and incubated with a primary antibody against total β -catenin (1:200), followed by 0.01% Tween 20 as detergent buffer and Alexa Fluor 594 (Invitrogen A11008, 1:5,000) as a secondary anti-mouse IgG antibody. The slides were stained with 4,6-diamidino-2-phenylindole (DAPI, Biolegend, 422801, 1:1,000 in PBS) as a nuclear counterstain, and mounted with Mowiol 4-88 (Calbiochem). Immunohistochemistry was performed on formalin-fixed, paraffin-embedded lymph-node sections as described previously 33 . Cryo-sections of mouse lymphnodes were stained with an fluorescein isothiocyanate-conjugated antibody against total β -catenin (BD Biosciences, 562505, 1:200), and human DLBCL sections were stained with a primary antibody against total β -catenin (BD Biosciences, 610153, 1:200), followed by a secondary anti-mouse IgG antibody (1:1,000, Dako REAL Detection System (labelled streptavidin-biotin), Dako, K5005).
Global proteome analysis. Suv39h1
− ;Bcl2;Suv39h1-ER T2 cells were sampled in ice-cold methanol after five days of ADR ± 4-OHT treatment. 50 μ g of the protein extracts were digested using an xt-PAL (CTC Analytics) pipetting robot with the Chronos software package (Axel Semrau), reduced with 1 mM tris(2-carboxyethyl) phosphine. Free sulfhydryl groups were carbamidomethylated using 5.5 mM choloroacetamide. The proteins were digested using 0.5 μ g sequencing-grade endopeptidase LysC (Wako) for 3 h at room temperature, and subsequently diluted with four volumes of 50 mM ammonium bicarbonate. Tryptic digestion occurred over 10 h at room temperature using 1 μ g of sequencing-grade trypsin (Promega). The reaction was stopped by adding trifluoroacetic acid to a final pH of 2. The peptides were purified using C18-stage tips (3M) 51 . By applying the dimethyl labelling technique, the untreated lymphoma samples, serving as the reference, were 'light'-labelled, whereas others (ADR ± 4-OHT-treated) were 'heavy'-labelled, on the xt-PAL machine by automatically adding 4 μ l light (+ 28 Da) or heavy (+ 32 Da) formaldehyde and 4 μ l cyanoborohydride to a final concentration of 0.8% 52 . The reaction was carried out overnight, quenched by 16 μ l of 50 mM ammonium bicarbonate buffer and acidified by 8 μ l 50% trifluoroacetic acid. The 'heavy'-and 'light'-labelled samples were mixed in a 1:1 ratio and measured as technical duplicates on a Q-Exactive mass spectrometer (Thermo Fisher) coupled to a Proxeon nano-LC system (Thermo Fisher) in data-dependent acquisition mode, selecting the top ten peaks for higher-energy collisional dissociation fragmentation. A three-hour gradient (solvent A: 5% acetonitrile, 0.1% formic acid; solvent B: 80% acetonitrile, 0.1% formic acid) was applied to the samples using a custom-made nano-LC column (0.075 mm × 250 mm, 3 μ m Reprosil C18, Dr. Maisch GmbH). The peptides were eluted in gradients of 4 to 76% acetonitrile and 0.1% formic acid in water at flow rates of 0.25 μ l min −1
. Mass spectrometric acquisition was performed at a resolution of 70,000 in the scan range of 300 to 1,700 m/z. Dynamic exclusion was set to 30 s and the normalized collision energy to 26 eV. For the automatic interpre-letter reSeArCH tation of the recorded spectral data, the MaxQuant software version 1.2.2.5 (Max Planck Institute) was used, with a multiplicity of 2 for dimethyl labelling 53 . An FDR of 0.01 was applied on the peptide and the protein level, and an Andromedabased search was performed using a mouse International Protein Index database (ipi.MOUSE.v3.84.fasta). Mass spectrometric measurement data were logtransformed regarding the heavy/light ratios using the R-statistical software (R Foundation for Statistical Computing). Three replicates were used to calculate mean values and significance levels using the Wilcoxon test. All identifications with a − log 10 -transformed P value > 1 were considered significant. Chromatin immunoprecipitation. Chromatin immunoprecipitation was performed according to Young and colleagues 54 with minor modifications. 1 × 10 7 cells were fixed for 20 min in a 1% formaldehyde solution. The fixation was stopped with 0.1 M glycine, the cell pellet was lysed and sonicated in 300 μ l buffer LB3 54 (Bioruptor Sonicator, two cycles of 15 min each at high power in pulsed mode (30 s on, 30 s off)). 30 μ l of 10% Triton X-100 was added and the sample was centrifuged at 13,000 rpm for 10 min at 4 °C. The supernatant was removed and an aliquot was retained as the input DNA sample. For immunoprecipitation, 140 μ l of the supernatant was mixed with 50 μ l of Dynabeads Protein G (Life Technologies/Invitrogen), pre-coated with 5 μ g of an H3K4me3 antibody (A5051-001P, Diagenode) or an H3K27me3 antibody (39155, Active Motif) and incubated at 4 °C overnight. After incubation, the beads were magnetically separated from the supernatant, washed and eluted. After reverse-crosslinking, RNaseA and proteinase K digestion 54 , the DNA was extracted with phenol/chloroform, and used as a template for qPCR. Sequence information of the specific primers used is available upon request. Enrichments were calculated according to the Δ Δ C t method, with Prame as endogenous control, and the input as calibrator. The values of the relative enrichments for the 4-OHT/ADR-treated samples were divided by the corresponding ADR sample values. Statistical evaluation. On the basis of previous experience with the Eμ -Myc transgenic mouse lymphoma model, sample sizes typically reflect three to five individual primary tumours as independent biological replicates. All quantifications from staining reactions (for example, immunostainings or SA-β -gal assays) reflect at least three samples with at least 100 events counted (typically in three different areas) each. For assessing long-term outcome after in vivo treatments, six or more tumour-bearing animals per arm were used. No statistical method was used to predetermine sample size. No data were excluded, all probes/animals that met proper experimental conditions were included in the analysis. For purposes of tumourinitiation assays, a transplanted mouse scored positive if a palpable lymphadenopathy developed at any time point during the observation period of 100 days. The tumour initiation data were analysed using the ELDA (Extreme Limiting Dilution Analysis) software package at http://bioinf.wehi.edu.au/software/elda/ (ref. 55 ) with a confidence interval of 95%. Unless stated otherwise, data are presented as arithmetic means ± standard deviation (s.d.) and statistical analyses were based on paired or unpaired two-sided t-tests. The data not following a normal distribution (by Kolmogorov-Smirnov test) were analysed by unpaired t-test with Welch's correction. Similar variance between groups was not assumed. P < 0.05 was considered statistically significant. The whisker plot boxes indicate the first and third quartiles with median, and the upper and lower bars minimum and maximum values. For GSEA, the non-parametric Kolmogorov-Smirnov test was applied. Significant enrichment was accepted when P < 0.05 and FDR < 0.25, thus using the default significance levels for the method. Data availability. Microarray datasets produced in our laboratory and analysed in this study are available at the Gene Expression Omnibus (GEO) repository of the National Center for Biotechnology Information, under the accession numbers GSE31099 and GSE44355, for control;Bcl2 and Suv39h1 Fig. 1a , measured by the efflux of a fluorescent substrate with and without the ABC transporter inhibitor verapamil. Representative plots of four independent lymphomas tested per genotype. e, Enhanced expression of the stem-cell marker CD34 in the RCK8 cell line or primary human B-cell leukaemia samples exposed to ADR treatment in vitro. Mean fluorescence intensity ± s.d. from three independent experiments (RCK8 cells) and five individual leukaemia cases determined by flow cytometry. Two-tailed, unpaired t-test with Welch's correction, * P < 0.05. f, TIS-mediated increase and verapamil-dependent blockage of ABC transporter activity in ADR-senescent RCK8 cells and primary human B-cell leukaemia samples as in e. One representative out of three independent experiments shown. g, SAS occurring in non-malignant senescence scenarios: GSEA of proliferation-or stem-cell-related gene sets (as in b) in publicly available transcriptome data representing different models of replicative senescence: primary human mammary epithelial cells in stasis or agonescence (GSE16058, 12 prestasis, 9 stasis and 4 agonescence individual biological samples), high-passage BJ human skin fibroblasts (GSE13330, n = 6 pairs of proliferating/senescent cells from individual donors) or high-passage primary human mesenchymal stem cells (GSE9593, n = 3 pairs of proliferating/senescent cells from individual donors). , c) . Two-tailed, unpaired t-test with Welch's correction, comparing ADR-and 4-OHT+ ADR pretreated lymphomas at p6, or 8 Gy-and 4-OHT+ 8 Gy at p5. * P < 0.05 (b, d). It is noteworthy that the superior growth and clonogenicity of post-senescent cells can be explained neither by rare cells that may simply have bypassed senescence, because the matching never senescent (that is, senescence bypasser) group presented with inferior clonogenicity, nor by an enhanced death rate of non-stem cells in the Suv39h1-proficient aliquot, because no significant differences in viability were observed between never senescent and previously senescent groups throughout these experiments. Viability determined by flow cytometry as thepercentage of annexin V/PI double-negative cells was typically greater than 80% and comparable between never senescent and previously senescent cells (not shown; the same applies for Figs 2a and 4a). Growth-promoting mutations are also unlikely, as senescent cells stopped replicating their DNA. e, f, Colony formation assay of untreated versus five-day-ADR-senescent human RCK8 lymphoma cells (e) or LT174T colon carcinoma cells (f) that were exposed to a shp53-lentivirus or mock infection on day five of ADR treatment, with p53 knockdown enabling outgrowth out of fully established senescence. As observed for mouse lymphoma cells, post-senescent RCK8 and LT174T cells, after just three passages, outperformed the clonogenic potential of tumor cells that were equally exposed to shRNA against p53 but never experienced senescence. Results represent mean colony numbers at indicated passages (each reflecting seven days in ADR-free methylcellulose medium) ± s.d., n = 3 independent experiments. Two-tailed, unpaired t-test with Welch's correction, comparing untreated shp53 versus ADR + shp53 at p5 (e) or p4 (f). * P < 0.05. g, TIS re-inducibility in Suv39h1 − ;Bcl2;Suv39h1-ER − ;Bcl2;Suv39h1-ER T2 cells exposed to the indicated Wnt inhibitors either simultaneously with ADR ± 4-OHT treatment (for the last 48 h of treatment), or at passage 2 after terminating ADR ± 4-OHT (never senescent and previously senescent; treated over 48 h with inhibitors).
Results show relative viability normalized to sample with no Wnt inhibitor treatment ± s.d. (n = 3 biologically independent samples). d, Colony formation of human LT174T colon carcinoma cells exposed to mock or shp53-lentivirus upon ADR-induced senescence, and further propagated in ADR-free medium (corresponding to passage 3 in Extended Data Fig. 3f) . Results show mean colony counts after seven-day exposure to indicated Wnt inhibitors ± s.d. (n = 3 independent experiments per group). Two-tailed, unpaired t-test with Welch's correction, * P < 0.05. e, Individual survival times of the six matched never senescent and previously senescent lymphoma pairs (shown collectively in Fig. 3d) . f, Individual survival times of mice bearing never senescent (left) and previously senescent lymphomas (right) after exposure to Wnt signalling inhibition by Ctnnb1 knockdown (shCtnnb1) or left uninhibited. The line plots represent the same matched never senescent and previously senescent lymphomas as in e. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 1. Sample size
Describe how sample size was determined. Based on previous experience with the Eμ-myc transgenic mouse lymphoma model, sample sizes typically reflect three to five individual primary tumors as independent biological replicates. For assessing long-term outcome after in vivotreatments, six or more tumor-bearing animals per arm were used.
Data exclusions
Describe any data exclusions. No data were excluded, all probes/animals that met proper experimental conditions were included in the analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
All experimental findings were reliably reproduced.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No randomization was used to allocate experimental groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
No blinding was used during allocation of experimental groups.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
